Sun Pharma has launched Leqselvi (deuruxolitinib, 8 mg) in the US for severe alopecia areata after settling IP litigation with Incyte. With favourable court rulings and FDA approval, the drug could generate $400 million by 2030 and potential peak sales of $900 million, strengthening Sun’s global specialty portfolio
Sun Pharma launches Leqselvi in the US
